203
Xilio Therapeutics, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
Assets
(positive)
Change from FY21 to FY25
millions USD
FY21:
FY22:
124
FY23:
48.1
FY24:
60.2
FY25:
145
(positive)
Change from FY21 to FY25
millions USD
FY21:
15.5
FY22:
14.7
FY23:
12.8
FY24:
10.8
FY25:
9.66
Total assets
Change from FY21 to FY25
millions USD
FY21:
218
FY22:
139
FY23:
60.9
FY24:
71.1
FY25:
155
Liabilities & Equity
(negative)
Change from FY21 to FY25
millions USD
FY21:
12.8
FY22:
21.1
FY23:
16.0
FY24:
27.3
FY25:
56.3
(negative)
Change from FY21 to FY25
millions USD
FY21:
19.9
FY22:
12.4
FY23:
8.14
FY24:
26.2
FY25:
63.1
(positive)
Change from FY21 to FY25
millions USD
FY21:
185
FY22:
106
FY23:
36.8
FY24:
17.6
FY25:
35.3
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
218
FY22:
139
FY23:
60.9
FY24:
71.1
FY25:
155
All amounts in millions USD